Insider Selling: Unum Therapeutics Inc (NASDAQ:UMRX) Insider Sells 11,485 Shares of Stock

Unum Therapeutics Inc (NASDAQ:UMRX) insider Seth Ettenberg sold 11,485 shares of the business’s stock in a transaction dated Thursday, October 25th. The shares were sold at an average price of $8.46, for a total value of $97,163.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Seth Ettenberg also recently made the following trade(s):

  • On Tuesday, September 25th, Seth Ettenberg sold 11,485 shares of Unum Therapeutics stock. The shares were sold at an average price of $12.47, for a total value of $143,217.95.

Shares of UMRX stock traded up $0.03 during trading hours on Thursday, hitting $7.47. The stock had a trading volume of 101,022 shares, compared to its average volume of 224,733. Unum Therapeutics Inc has a one year low of $6.75 and a one year high of $17.66.

Unum Therapeutics (NASDAQ:UMRX) last issued its quarterly earnings data on Monday, November 12th. The company reported ($0.34) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.35) by $0.01. Unum Therapeutics had a negative return on equity of 382.71% and a negative net margin of 404.34%. The company had revenue of $2.04 million for the quarter, compared to analysts’ expectations of $2.29 million. As a group, analysts predict that Unum Therapeutics Inc will post -1.56 EPS for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Spark Investment Management LLC purchased a new position in shares of Unum Therapeutics during the second quarter valued at approximately $186,000. Wasatch Advisors Inc. boosted its position in shares of Unum Therapeutics by 5.3% during the second quarter. Wasatch Advisors Inc. now owns 267,625 shares of the company’s stock valued at $3,840,000 after buying an additional 13,525 shares during the period. Bank of New York Mellon Corp purchased a new position in shares of Unum Therapeutics during the second quarter valued at approximately $177,000. Cowen Inc. purchased a new position in shares of Unum Therapeutics during the second quarter valued at approximately $8,341,000. Finally, BlackRock Inc. purchased a new position in shares of Unum Therapeutics during the second quarter valued at approximately $6,403,000. 51.81% of the stock is currently owned by institutional investors.

UMRX has been the topic of several research analyst reports. Cowen restated a “hold” rating on shares of Unum Therapeutics in a research report on Monday. Zacks Investment Research upgraded Unum Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, November 6th. Morgan Stanley lifted their target price on Unum Therapeutics from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Thursday, October 11th. Finally, Wedbush lifted their target price on Unum Therapeutics from $18.00 to $20.00 and gave the stock an “outperform” rating in a report on Tuesday, August 14th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Unum Therapeutics presently has a consensus rating of “Buy” and an average target price of $20.67.

TRADEMARK VIOLATION WARNING: “Insider Selling: Unum Therapeutics Inc (NASDAQ:UMRX) Insider Sells 11,485 Shares of Stock” was reported by Enterprise Leader and is owned by of Enterprise Leader. If you are viewing this article on another domain, it was illegally copied and republished in violation of international copyright legislation. The correct version of this article can be accessed at https://theenterpriseleader.com/2018/11/22/seth-ettenberg-sells-11485-shares-of-unum-therapeutics-inc-umrx-stock.html.

Unum Therapeutics Company Profile

Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. Its lead product candidate is the ACTR087 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory non-Hodgkin lymphoma.

Further Reading: Find a Trading Strategy That Works

Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply